LAUSR

BACKGROUND The Colloid Cyst Risk Score (CCRS) was devised to identify symptomatic colloid cyst patients and stratify risk of hydrocephalus. The CCRS considers patient age, presence of headache, colloid cyst diameter, fluid-attenuated inversion recovery (FLAIR) hyperintensity, and location within the third ventricle. OBJECTIVE The purpose of this study was to independently evaluate the validity of the CCRS. METHODS Patients with a colloid cyst of the third ventricle were identified retrospectively from institutional billing records and radiology report archives. Patients without a confirmed diagnosis of colloid cyst of the third ventricle or magnetic resonance imaging (MRI) of the brain were excluded. Data were collected via retrospective chart review. RESULTS One hundred fifty-six patients met inclusion and exclusion criteria. In our cohort, the CCRS stratified symptomatic patients and patients with hydrocephalus across all scores (p<0.001). From CCRS two to five, the percentage of symptomatic patients increased from 13% to 100%, while the percentage of patients with hydrocephalus increased from 8% to 83%. Simple logistic regression showed that total CCRS, headache, axial diameter, FLAIR hyperintensity, and risk zone were all highly predictive of symptomatic status and hydrocephalus (p<0.001). Logistic regression with receiver operator curves for the CCRS demonstrated an area under the curve (AUC) of 0.914 for symptomatic colloid cysts and an AUC of 0.892 for colloid cysts with hydrocephalus. CONCLUSION Our data analysis validates the predictive value of the CCRS for both symptomatic status and hydrocephalus and supports the use of the CCRS in risk-stratification and clinical decision-making.